NASDAQ · ELDNHealthcarePharmaceuticals

Eledon Pharmaceuticals news

$2.50−5.30%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days1English, de-duplicated

Positive1100% of coverage

Neutral00%

Negative00% of coverage

About Eledon Pharmaceuticals

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

GlobeNewswire Inc.Sep 22, 7:00 AM ET▲ Positive

The company announced positive Phase 2 long-term data showing tegoprubart's superiority over standard-of-care tacrolimus in kidney transplant patients, with statistically significant improvements in kidney function and zero rejections beyond six months. FDA Fast Track designation accelerates development pathway and increases likelihood of successful commercialization. Advancement to Phase 3 trial in Q4 2026 represents significant clinical progress.

Also mentions ELDN

Articles that tag ELDN but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology